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The β-lactams retain a central place in the antibacterial armamentarium. InGram-negative bacteria, β-lactamase
enzymes that hydrolyze the amide bond of the four-membered β-lactam ring are the primary resistance
mechanism, with multiple enzymes disseminating on mobile genetic elements across opportunistic pathogens
such as Enterobacteriaceae (e.g., Escherichia coli) and non-fermenting organisms (e.g., Pseudomonas
aeruginosa). β-Lactamases divide into four classes; the active-site serine β-lactamases (classes A,C andD) and
the zinc-dependent or metallo-β-lactamases (MBLs; class B). Here we review recent advances in mechanistic
understanding of each class, focusing upon how growing numbers of crystal structures, in particular for β-lactam
complexes, and methods such as neutron diffraction and molecular simulations, have improved understanding
of the biochemistry of β-lactam breakdown. A second focus is β-lactamase interactions with carbapenems, as
carbapenem-resistant bacteria are of grave clinical concern and carbapenem-hydrolyzing enzymes such as
KPC (class A) NDM (class B) and OXA-48 (class D) are proliferating worldwide. An overview is provided of
the changing landscape of β-lactamase inhibitors, exemplified by the introduction to the clinic of combinations of
β-lactams with diazabicyclooctanone and cyclic boronate serine β-lactamase inhibitors, and of progress and
strategies toward clinically useful MBL inhibitors. Despite the long history of β-lactamase research, we contend
that issues including continuing unresolved questions around mechanism; opportunities afforded by new
technologies such as serial femtosecond crystallography; the need for new inhibitors, particularly for MBLs; the
likely impact of new β-lactam:inhibitor combinations and the continuing clinical importance of β-lactams mean
that this remains a rewarding research area.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
β-Lactam antibiotics
The discovery of penicillin in 1929 [1] is rightly
recognized as a milestone in the history of medicine,
and its introduction to the clinic in the 1940s revolu-
tionized our ability to treat bacterial infections. Despite
enormous progress in the field of antimicrobial chemo-
therapy in the more than 70 years after the first use of
penicillin, as the centenary of Fleming's work ap-
proaches, theβ-lactams remain the cornerstones of the
antibacterial arsenal. The fact that they remain both theAuthor. Published by Elsevier Ltd. T
g/licenses/by/4.0/).
: C. L. Tooke, P. Hinchliffe, E. C. Braggint
cular Biology, https://doi.org/10.1016/j.jmb.single most prescribed antibiotic class and the most
important in terms of sales [2] attests to their continuing
central role in the treatment of bacterial infections.
β-Lactams, like other antimicrobial classes, have
undergone continuous development since their
original introduction in order to improve properties
such as potency, spectrum of activity, pharmacoki-
netic and safety profiles and to counter the emer-
gence of resistance [3]. At present, four main classes
of β-lactam antimicrobials are in clinical use (Fig. 1).
These comprise three types of bicyclic structure: the
penicillins (1), in which the four-membered β-lactam
ring is fused to a thiazolidine ring; the cephalosporins
(2), where the fusion partner is a six-membered
his is an open access article under the CC BY license
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Fig. 1. Structures of representative β-lactams and β-lactamase inhibitors. 1. Penicillin scaffold. 2. Cephalosporin scaffold.
3. (1-methyl) Carbapenem scaffold. 4. Hydrolyzed carbapenem (Δ2-pyrroline form). 5. Hydrolyzed carbapenem (Δ1-pyrroline
form). 6. Monobactam scaffold. 7. Clavulanic acid. 8. Avibactam. 9. Relebactam. 10. Vaborbactam. 11. Bicyclic boronate.
2 Review: β-Lactamases and β-Lactamase Inhibitorsdihydrothiazine; and the carbapenems (3), where the
bicyclic system is completed by a five-membered
pyrroline. A fourth class, the monobactams (6) are
monocyclic systems. While each class was originally
identified as a natural product (penicillin in 1929,
cephalosporins by Newton and Abraham [5] (building
on the work of Brotzu [4]) in 1954, olivanic acid
(carbapenem) by Brown and co-workers [6] in 1976
and monobactams by Sykes and Imada and theirPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.respective co-workers [7,8] in 1981], each has since
undergone extensive programs of modification to
create arrays of semi-synthetic derivatives.
The antibacterial activity of β-lactams was identified
by Tipper and Strominger [9] as based on their
resemblance to the terminal D-Ala–D-Ala moiety of the
peptidoglycan stem pentapeptide, with the β-lactam
amide and adjoining carboxylate (or, in the case of
monobactams, sulfonic acid) groups serving to mimicn, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
3Review: β-Lactamases and β-Lactamase Inhibitorsthe peptide bond and terminal carboxylate of D-Ala–D-
Ala. Activity then arises from reaction of the β-lactam
ring with the nucleophilic serine of target penicillin-
binding proteins (PBPs), leading to opening of the ring
and irreversible PBP acylation [10] that prevents
formation of peptidoglycan transpeptide cross-links. In
consequence, modification that allows for retention of
antibacterial activity is possible at several positions on
the β-lactam scaffold: C6 of penicillins, C7 and C3 of
cephalosporins, C2 of carbapenems and C3 of
monobactams. Key developments arising from such
modifications include introduction of aminopenicillins
(e.g., ampicillin) that extended antibacterial activity of
penicillins to include Gram-negative bacteria [11];
introduction of methicillin to counter penicillin-resistant
strains ofStaphylococcus aureus [12]; and introduction
of oxyiminocephalosporins [13] (e.g., cefotaxime,
ceftazidime) to counter emergence of β-lactamase-
mediated resistance in Gram-negative bacteria.
β-Lactamase mediated β-lactam resistance
Aswith other antimicrobial classes, extensive use of
β-lactams has led to the emergence and dissemina-
tion of resistance. Resistance can occur by multiple
mechanisms, including modification of the target
(mutation or expression of alternative PBPs), reduc-
tion in cell permeability through downregulation of
porins required for β-lactam entry, over-expression
of efflux systems and production of modifying or
degradative enzymes [14]. In the case of β-lactams,
enzyme-mediated resistance arises from the activity
of β-lactamases, enzymes produced by both Gram-
positive and Gram-negative bacteria that hydrolyze
the β-lactam amide [15]. It is not always appreciated
that enzymes able to degrade penicillin were identified
inEscherichia coli even before its first use inman [16],
although as initial penicillin use focused largely on
infections by Gram-positive pathogens, the signifi-
cance of this finding was not immediately apparent.
β-Lactamases, however, quickly became clinically
important as resistance in S. aureus arising from
production of the PC1 enzyme [17] (encoded by the
blaZ gene) rapidly compromised penicillin effective-
ness. This and the successful countering of PC1-
producing organisms through introduction ofmethicillin
[12] heralded the beginning of an “arms race” between
medicinal chemists and bacterial evolution that con-
tinues to this day and that has seen the introduction
of new β-lactams lead to emergence of new β-
lactamases both by mutation of previously known
families and dissemination of genes encoding new
enzymes. Despite the initial importance of PC1-
mediated penicillin resistance in S. aureus, in Gram-
positive bacteria, the emergence of strains carrying
PBP alterations has largely superseded β-lactamase
production as the primary mechanism of β-lactam
resistance [18]. In consequence, this reviewwill largely
focus onGram-negative bacteria, where β-lactamasesPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Braggint
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.remain the primary β-lactam resistance mechanism,
although it is important to note that in the clinic
resistance is very oftenmultifactorial and phenotype is
driven by combinations ofmechanisms that frequently
include permeability modifications and/or efflux pump
upregulation in addition to β-lactamase production. A
further complication is the increasing prevalence of
strains expressing multiple β-lactamases, often
encoded upon single multiresistance plasmids (for
recent reviews, see Refs. [19,20]).
Classification of β-lactamases
Identification of growing numbers of β-lactamases,
coupled with availability of protein, and subsequently
nucleotide, sequence information, established that
theseenzymesdonot comprisea singlehomogeneous
group but instead can be subdivided into multiple
classes. Furthermore, as enzyme activity against
different β-lactam substrates began to be reported, it
became apparent that β-lactamases encompass a
range of biochemical properties. With the explosion of
sequence information, the number of identified β-
lactamases has undergone a near-exponential in-
crease; at the time of writing, the β-lactamase database
(www.bldb.eu [21]) contains over 4300 such enzymes
that have undergone varying degrees of
characterization.
Two systemsof classifying this array of enzymes are
in use: the Bush–Jacoby–Medeiros activity-based
system [22] and the Ambler system [23] based on
sequence information. The latter divides β-lactamases
into four distinct classes, termed A, B C and D (Fig. 2),
identified on the basis of specific sequence motifs but
also distinguished by fundamental differences in
hydrolytic mechanism. A further fundamental division
is between the three classes (A, C andD) of active-site
serine enzymes (seine β-lactamases; SBLs) and class
B that comprises a heterogeneous group of zinc
metalloenzymes (metallo-β-lactamases, or MBLs).
SBLs are distantly related to PBPs [24] (with which
they share an invariant Ser–Xaa–Xaa–Lys motif),
employ this serine as the reaction nucleophile and
hydrolyze β-lactams via a covalent acylenzyme
intermediate. MBLs instead utilize a metal-activated
water nucleophile to drive the hydrolytic reaction.
Although all four classes are widely distributed in
multiple species of clinically significant and environ-
mental bacteria, within each class, a few enzyme
families have been spectacularly successful and have
disseminated widely across the most important bacte-
rial pathogens. These are generally considered to be
Gram-negative bacteria responsible for opportunistic
healthcare-associated infections of immunocompro-
mised patients, including Enterobacteriaceae such as
E. coli and Klebsiella pneumoniae and non-fermenting
species such as Pseudomonas aeruginosa and
Acinetobacter baumannii. Key enzyme families in-
cludeTEM,SHV,CTX-MandKPC (classA); NDMandon, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
Fig. 2. Overall structure of representative β-lactamases from each class. Crystal structures of β-lactamases from classes
A, B, C and D. Catalytic important residues of serine-β-lactamases (serine 64/70 and lysine 67/73, labeled) are colored
orange, and themetallo-β-lactamase zinc ions are shown as gray spheres. (a) Class A KPC-2 (PDB 5ul8). (b) Class BNDM-1
(PDB 5zgy). (c) Class C AmpC (PDB 1ke4). (d) Class D OXA-48 (PDB 3hbr). Figure (and other structural Figures) generated
with Pymol (www.pymol.org).
4 Review: β-Lactamases and β-Lactamase InhibitorsVIM (class B); and CMY and ADC (class C). Class D
enzymes are all termed oxacillinase (OXA); particular
concern surrounds the OXA-23 and 24/40, and the
OXA-48 groups, responsible for carbapenem resis-
tance in A. baumannii and Enterobacteriaceae,
respectively. (It is apparent from the above that the
field is considerably complicated by historical but now
well-established inconsistencies of nomenclature.)
This review will focus on recent advances in our
mechanistic understanding of these and other key
enzymes from each of the four Ambler classes, as
derived primarily from the growing availability of
structural (crystallographic) information describing
how β-lactamases interact with their substrates.
We will then briefly consider how new develop-
ments in the area of β-lactamase inhibitors promise
to enable some β-lactamase-mediated resistance
to be overcome. A particular interest is the inter-
actions of β-lactamases with carbapenems, as
these are increasingly “first-choice” agents forPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.empiric therapy of healthcare-associated Gram-
negative infections [25]. In the light of the continuing
lack of new antibiotics with anti-Gram-negative
activity, carbapenem resistance is a cause of much
clinical concern [26,27].
Mechanistic overview of serine β-lactamases
Although the three classes of SBLs differ substan-
tially in sequence, all employ an acylation–deacylation
mechanism, reminiscent of that of serine proteases, in
which the nucleophilic serine is activated by a general
base, attacks the carbonyl carbon of the scissile β-
lactam amide bond and generates the acylenzyme
intermediate via a tetrahedral oxyanion transition state
(Fig. 3). Resolution of this species occurs when a
water molecule, the so-called deacylating water, is
activated by a general base for hydrolysis of the
acylenzyme and liberation of the degraded product.
The three Ambler classes, however, divergen, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
Fig. 3. Mechanistic overview of serine β-lactamases. Figure shows hydrolysis of generic penicillin substrate. (a)
General base B1 activates Ser for nucleophilic attack on the amide carbonyl carbon (C7) generating covalent acylenzyme
(c) via tetrahedral oxyanionic acylation transition state (b). General base B2 activates incoming deacylating water molecule
DW for nucleophilic attack on the acylenzyme carbonyl liberating penicilloate product (e) via tetrahedral deacylation
transition state (d). For clarity, details of proton transfers to N4 and Ser are omitted. Note that the identities of bases B1 and
B2 vary between β-lactamase classes.
5Review: β-Lactamases and β-Lactamase Inhibitorsmechanistically, in particular with respect to the
identities of, and precise interactions made by, the
necessary general base(s). In classes A and C, this
represents a long-standing source of debatewithin the
field.Class A β-lactamases
The class A enzymes comprise the most widely
distributed and intensively studied of all β-lactamases.
Notable class A enzymes include PC1, responsible
for penicillin failure in S. aureus; TEM [28] (named
for patient Temoneira), the first plasmid-borne β-
lactamase identified in Gram-negative bacteria and
active against aminopenicillins and early cephalospo-
rins; SHV (sulfhydryl variant, an enzyme with similar
activity to TEM, originally identified on the chromosome
of K. pneumoniae [29] and subsequently mobilized
onto plasmids); CTX-M [30] (cefotaximase, an enzyme
inherently active against the oxyiminocephalosporin
cefotaxime and that has rapidly disseminated world-
wide); andKPC [31] (K. pneumoniae carbapenemase).
Key to the success of enzymes such as the TEM, SHV
and CTX-M families has been their dissemination on
plasmids and other mobile genetic elements across a
range of Gram-negative pathogens, particularly the
Enterobacteriaceae, and their ability to expand their
spectrumof activity asnewsubstratesare introduced toPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Braggint
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.the clinic. Thus, acquisition of point mutations that
enable TEM and SHV to hydrolyze oxyiminocephalos-
porins such as cefotaxime and ceftazidime has
generated the so-called “extended-spectrum” pheno-
type (extended-spectrum beta-lactamases, or ESBLs);
CTX-M enzymes, which possess some inherent
activity against some such substrates, also accumulate
mutations to extend their activity andprovide resistance
to an enlarged range of β-lactams. ESBLs now
significantly threaten the continued effectiveness of
cephalosporins in a number of clinical contexts [32].
The extensive literature on mutational adaptation in
class A enzymes has been recently reviewed by
Palzkill [33]; hence, this will not be considered further
here. We instead focus on two aspects of class A
biochemistry—the continuing quest for understanding
of the acylation mechanism and the basis for their wide
variation in activity against carbapenem substrates.
The acylationmechanismof classA β-lactamases
Despite the wealth of accumulated information, the
acylation mechanism of the class A enzymes remains
a source of debate and controversy. Two main
proposals (Fig. 4) have been put forward, differing in
the mechanism by which the serine nucleophile is
activated for attack upon the β-lactam carbonyl carbon
and, specifically, the identity of the residue acting as
the general base in this process. Two conservedon, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
Fig. 4. (A) alternative acylation mechanisms for class A β-lactamases. (a) Apoprotein active site shows Lys73
protonated and Glu166 deprotonated. Ser70 may be activated for nucleophilic attack upon the β-lactam carbonyl by
Glu166 via a water molecule (b). Alternatively, substrate binding reorganizes protonation in the active site such that neutral
Lys73 activates Ser70 (c). The transition state (d) resolves to the acylenzyme intermediate (e) by protonation of the amide
nitrogen from Ser130.
6 Review: β-Lactamases and β-Lactamase Inhibitorsresidues, Lys73 (part of the SBL SXXK motif) and
Glu166, havebeenproposed to fulfill this function, with
both proposals supported by experimental evidence
arising from crystallographic studies of enzyme
complexes, high-level computational simulations
and biochemical investigations of enzyme mutants.
Recent contributions in this area stem primarily from a
growing availability of high-resolution crystal struc-
tures of both free enzymes and covalent complexes,
providing direct evidence of protonation states in the
β-lactamase active site. These include an increasing
number of neutron diffraction studies, made possible
by availability of more powerful neutron sources
capable of delivering improved diffraction from macro-
molecular crystals. An attractive prospect is presented
by the growing availability of X-ray free electron laser
sources that, when coupled with rapid mixing or otherPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.reaction initiation technologies, offer the prospect of
applying serial femtosecond crystallography (SFX)
techniques [34] to capturemechanistically relevant but
transiently populated species. The inherently favorable
diffraction characteristics of many β-lactamase crys-
tals make these appealing initial targets for application
of SFX to studies of enzyme mechanism, the first
results of such studies are starting to emerge [35–37].
Recent evidence supporting involvement of Glu166
as the general base for acylation is provided by
both ultrahigh-resolution X‐ray and neutron diffraction
studies of the apo-enzymes of CTX-M-9 [38] and
Toho-1 [39] (also known as CTX-M-44), which
consistently depict active-site hydrogen bonding
networks connecting Ser70 and Glu166 via a con-
served water molecule and identify Lys73 as present
in the protonated form and thus unable to activaten, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
7Review: β-Lactamases and β-Lactamase InhibitorsSer70. Moreover, quantum mechanics/molecular
mechanics (QM/MM) calculations on TEM-1 [40–42]
support Glu166 as the general base, on the basis that
calculated energetic barriers correlate with values
derived from experiment and stable species with
Lys73 neutral and Glu166 protonated were not
observed during the simulations.
The ability of Lys73 to act as general base is
supported by the generation of stable acylenzyme
complexes, albeit at reduced rates, by mutants at
Glu166 [43,44], consistent with the widely accepted
role of this residue as the general base in the
deacylation reaction [45,46], but implying the exis-
tence of a viable alternative acylation mechanism. In
contrast, alanine mutants of Lys73 have been used to
trap non-covalent Michaelis complexes [47], indicative
of an essential role for Lys73 in acylation, and high-
resolution X‐ray [48] and neutron [49] structures of
some acylenzyme complexes of Glu166 mutants
show Lys73 to be deprotonated, suggesting that
binding of substrate can reduce its pKa sufficiently
for this to occur. A combined X‐ray/neutron study of a
preacylation complex, generated using a CTX-M-44
(Toho-1) Ser70Gly mutant, also reaches this conclu-
sion and is supported by QM/MM calculations of
energy barriers for proton transfer from Lys73 to
Glu166 via Ser70, which reduce in models of the
substrate complex compared to the apoenzyme [50].
Similarly, ab initio QM/MM calculations [51] have also
supported existence of a Lys73-dependent acylation
pathway in addition to a Glu166-dependent mecha-
nism. An alternative approach utilizing an analogue of
the acylation transition state [52] also indicates proton
transfers induced by ligand binding and postulates a
low-barrier hydrogen bond to Lys73 as an important
contributor to stabilizing the Ser70 nucleophile.
Despite these and other advances, however, uncer-
tainties remain: the necessary use of enzymemutants
or substrate analogues in structural characterization of
transient species may alter active-site hydrogen
bonding networks, while QM/MM simulations remain
sensitive to factors including the starting structure/
initial model, basis set and QM method used, with
consequences for the accuracy of predicted values
for energy barriers. Thus, despite substantial recent
advances, the acylation mechanism for class A β-
lactamases remains to be fully resolved.
Carbapenem hydrolysis by class A β-lactamases
An area of investigation of class A β-lactamases of
much current interest and both mechanistic and
clinical relevance concerns the interactions of these
enzymes with carbapenems. Carbapenems, intro-
duced to the clinic in 1985 in the form of imipenem [53]
(in combination with the renal dipeptidase inhibitor
cilastatin required to avoid breakdown in vivo),
possess both potent antimicrobial activity through
inhibition of PBPs, and the ability to effectively acylate,Please cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Braggint
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.and form long-lived acylenzymes with, the majority of
serine β-lactamases. This inhibitory activity encom-
passes the most widely disseminated class A
enzymes of the TEM, SHV and CTX-M families.
However, new β-lactamases able to hydrolyze carba-
penems have emerged with increasing carbapenem
use; in the case of class A, themost important of these
are theKPCenzymes [54], which nowhaveworldwide
distribution [31]. The mechanistic basis for the activity
of these enzymes against carbapenems, which other
class A β-lactamases enzymes lack, is attracting
continued attention.
Carbapenemsare distinguished fromother β-lactams
by theability of thepyrroline ring to tautomerizebetween
the Δ2 and Δ1 forms (Fig. 1, 4, 5), characterized by
migration of the double bond from C2_C3 to C3_N.
Knowles and co-workers [55,56] identified that, on
reaction with TEM β-lactamase, bound carbapenem,
initially in the Δ2 tautomer, could either deacylate or
alternatively isomerize to the more inert Δ1 form that
accumulated as a stable enzyme-bound species.
Subsequent work [57] identified protonation at C3,
catalyzed by the Arg244 residue present in TEM-1 and
many other class A enzymes, as central to this process.
Crystal structures of acylenzyme complexes generated
by exposure of class A enzymes to carbapenems
(Fig. 5) have in due course described binding modes of
both theΔ2 andΔ1 tautomers, but less expectedly also
revealed an ability, in the TEM [58] and SHV [59]
enzymes, of the acylenzyme carbonyl to migrate
between positions within and outside the oxyanion
hole formedby thebackboneamidesof residues70and
237. In the case of SHV-1, both of these conformations
are observed in a single high-resolution structure
(Fig. 5a). Together with Raman crystallographic studies
of SHV-1:carbapenem complexes [60], that exploit the
distinctive signature of the β-lactam acylenzyme
carbonyl to resolve it from bulk protein background,
and establish that an initial dual (Δ1/Δ2) population
resolves to the Δ1 form, these provide a picture of
carbapenem binding in which conformational flexibility
of the acylenzyme prevents facile deacylation, enabling
isomerization to and accumulation of the stable Δ1
species. An additional key observation is that the 6α-
hydroxyethyl substituent of carbapenems adopts posi-
tions that enable interaction with elements of the active
site important to deacylation, Glu166 in the case of the
Mycobacterium tuberculosis BlaC enzyme [61] and the
deacylating water molecule in SHV-1 complexes [59]. It
is then highly likely that such interactions are able to
change the pattern of hydrogen bonding in the active
site, deactivating the complex for deacylation and
instead favoring the competing isomerization reaction.
A central question is then how classA β-lactamases
with carbapenemase activity, such as KPC, avoid
inhibitory interactionswith carbapenems. As structural
information on such enzymes became available
[62–64], it was recognized that they are distinguished
from other class A β-lactamases by possession of aon, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
Fig. 5. Carbapenem complexes of class A β-lactamases. Close-up views of class A: carbapenem complexes,
carbapenem acylenzymes are covalently attached to Ser70. Note hydrogen bonding interactions of the acylenzyme
carbonyl with the oxyanion hole formed by the backbone amides of residues 70 (nucleophilic Ser) and 237. (a) SHV-1:
meropenem acylenzyme (PDB:2ZD8). Meropenem is modeled in two conformers with the carbonyl oxygen either pointing
into the oxyanion hole (interacting with Ala237 and Ser70) or pointing away from the oxyanion hole (interacting with
Ser130). In both models, the meropenem R group is not modeled due to disorder. (b) KPC-2:faropenem non-covalent
product complex (5UJ4). (c) SFC-1:meropenem acylenzyme (4EV4). (d) GES-5:imipenem acylenzyme (4H8R). Important
residues for catalysis and substrate binding (labeled) are represented as sticks, and the deacylating water is displayed as
a red sphere. Distances (Å) are displayed as dashed lines.
8 Review: β-Lactamases and β-Lactamase Inhibitorsdisulfide bridge between residues 69 and 238, and
that their active sites are to some degree expanded
compared to those of enzymes inhibited by carba-
penems [64], although there are not otherwise gross
changes to the active site. Moreover, the importance
of the disulfide varies between enzyme families; it
appears essential to activity of SME-1 against any β-
lactam substrate [65], and its disruption by mutation
severely destabilizes the NMC-A and SFC-1 en-
zymes, but a Cys69Gly mutant of GES-5 is destabi-
lized but remains catalytically competent [66]. These
authors conclude that the disulfide is structurally
important, but is not an essential and defining
requirement for carbapenemase activity.
More recently, crystal structures have become
available for carbapenem acylenzymes of the SFC
[67] and GES [68] enzymes (Fig. 5, c, d), providing
direct observation of carbapenem binding to enzymes
with carbapenemase activity. Compared to carbapen-
em acylenzymes of other class A β-lactamases, these
reveal bound carbapenemexclusively in theΔ2, rather
than Δ1, form and show that the carbapenem 6α-
hydroxyethyl group is oriented to make stable
hydrogen-bonding interactions, with Asn132, that
preclude deactivating contacts with the deacylatingPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.water molecule. The expanded active site of class A
carbapenemasesmay then facilitate this interaction by
enabling the necessary rotation about the C6\C7
bond, a conclusion that is supported by molecular
dynamics (MD) simulations of SFC-1. In the GES
enzymes, where carbapenemase activity is restricted
to specific point variants of what are otherwise
extended-spectrum enzymes and remains relatively
modest, but still clinically relevant, an additional
consideration is the longevity of hydrogen-bonding
interactions involving Glu166. In GES variants
(e.g., GES-5) that hydrolyze carbapenems, persis-
tentH-bonds toSer170are proposed, baseduponMD
simulations, to maintain Glu166 in a position and
orientation necessary for deacylation. GES enzymes
lacking Ser170, such as GES-1, are unable to
hydrolyze carbapenems.
KPC enzymes are by far the most clinically
significant of the class A carbapenemases, due to
their global distribution in species, principally K.
pneumoniae, responsible for the majority of opportu-
nistic infections of compromised patients in the
healthcare setting [31]. Although structural information
on interactions of KPC with β-lactams remains limited,
numerous studies have utilized both natural variantsn, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
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9Review: β-Lactamases and β-Lactamase Inhibitors[69] and laboratory mutants [70–72] to investigate the
involvement of specific residues in KPC in activity
against a range of substrates, including carbapenems.
While a carbapenem acylenzyme complex for KPC
remains elusive, the structure of a complex with the
hydrolysis product of the penem faropenem (Fig. 5b
[73]) is consistent with many of these findings,
implicating residues such as Pro104, Thr237 and
Val240 in substrate binding in the context of an active
site that is overall more hydrophobic than that of
enzymes such as CTX-M. Nevertheless, high-level
computational approaches, typically involving many
microseconds of accumulated simulations, have in-
creasingly been applied to study dynamics and
conformational transitions in KPC with the aim of
establishing a basis for carbapenemase activity. A
common finding is that movement of Trp105, a residue
that lies on one side of the active site cleft and that
adopts multiple conformations in crystal structures of
the unliganded enzyme [73], defines transitions be-
tween states that differ with respect to their compe-
tence for β-lactam turnover. In simulations of
carbapenem acylenzyme complexes, committor anal-
ysis identifies the conformation of the Trp105 loop as
one factor differentiating so-called “permissive” confor-
mations (in which the β-lactam acylenzyme carbonyl
occupies the oxyanion hole and the deacylating water
is present) from “non-permissive” conformations with
the carbonyl outside the oxyanion hole and the
deacylating water absent [74]. In multiple-replica
parallel tempering metadynamics simulations, that
access timescales not available through conventional
methodologies, unliganded KPC is shown to undergo
motions of active site regions, including Trp105 and the
omega-loop containing Glu166, that are related to
hydrophobic networks in the individual α and α/β
domains and that direct interactions with substrates
[75]. Experimental studies of site-directed mutants
support these findings by identifying Trp105 as a
determinant of KPC activity [71]. QM/MM investiga-
tions of carbapenem hydrolysis by class A enzymes,
however, remain in their infancy, in part as a result of
the relative paucity of crystal structures on which to
base starting models. However, a comparison of
carbapenem deacylation by a range of class A β-
lactamases [76] demonstrated that QM/MM ap-
proaches could successfully discriminate between
enzymes with carbapenemase activity and acylen-
zyme systems resistant to deacylation.
When considered together with studies on other
class A carbapenemase systems such as those
described above, an accumulating body of evidence
suggests that activity against carbapenems imposes
specific spatial requirements on the class A β-
lactamase active site that are necessary to orient
bound carbapenems for hydrolysis, but may be more
stringent than those associated with other β-lactam
substrates. Specifically, a balance may exist be-
tween two potentially conflicting requirements: thePlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Braggint
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.need to rotate the carbapenem 6α-hydroxyethyl
substituent away from the deacylating water and to
constrain the acylenzyme carbonyl within the oxya-
nion hole and prevent access to “non-permissive”
conformations. It is likely that multiple structural
features, including the conformations of the Trp105
and the omega loops, and the Cys69–Cys238
disulfide bridge, provide the necessary constraints
upon the orientation of bound substrates. In this
context, it is notable that clinical KPC point variants
with increased activity against the (notably bulky)
oxyiminocephalosporin ceftazidime exhibit reduced
activity against carbapenems [69], indicating a
possible association between active-site expansion
and reduced carbapenemase activity.Class B β-lactamases
The class B, zinc-dependent, MBLs are unrelated to
known PBPs and instead are members of a large,
ancient and widely distributed metallohydrolase super-
family. These enzymes are predominantly found in
prokaryotes and act upon a range of substrates
extending from various small-molecules (thiolesters,
phosphonates) though to nucleic acids [77,78], and
in higher eukaryotes are involved in DNA repair and
RNA processing pathways [79]. MBLs are distin-
guished by a His-Xaa-His-Xaa-Asp motif that forms a
metal center located at the interface of the two β-sheets
that comprise the core of the protein. It is proposed that
the fold originally arose by duplication of an ancestral
αβ domain. The identities of the residues that make up
this center and its stoichiometry and architecture define
three distinct MBL subfamilies (termed B1, B2 and B3).
B1 enzymes, the most clinically important, possess a
binuclear zinc center comprising tri-His (termed Zn1)
andCys-His-Asp (Zn2)metal sites; in B3 enzymes, the
Zn2-coordinating Cys is replaced by an additional His
residue; and in B2 enzymes, the first His of the defining
motif is replaced by Asn, resulting in a mononuclear
enzyme in which only the Zn2 site is occupied [80,81].
In the binuclear enzymes (Fig. 6), metal coordination is
completed by water molecules, one of which (the so-
called “bridging” water) connects the two metal ions,
and the other (sometimes termed the “apical” water) is
bound to Zn2. The geometry of Zn1 is normally
considered to be tetrahedral; Zn2 has been described
as trigonal bipyramidal or distorted square pyramidal.
With the possible exception of the IMP enzymes [82],
MBLs are isolated as zinc enzymes, although they are
active when reconstituted as other metallated forms
(e.g., see Refs. [83–85]), and other superfamily
members utilize a range of other metal ions [77,79].
As β-lactamases, the MBLs are notable for their
exceptionally broad spectrum of activity, which for the
binuclear enzymes encompasses penicillins, cephalo-
sporins and carbapenems, although they show little or
no activity against monobactams [86,87].on, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
Fig. 6. Active-site architecture of class B metallo-β-lactamases and their carbapenem complexes. Close-up views of
native metallo-β-lactamase active sites (left) and hydrolyzed carbapenem products (labeled) bound in the active sites
(right). (a) B1 NDM-1 (PDBs 5zgx and 5ypk; left and right, respectively). (b) B1 VIM-1 (5n5g and 5n5i). (c) B3 SMB-1 (3vpe
and 5b1u).
10 Review: β-Lactamases and β-Lactamase InhibitorsCompared to other superfamilymembers and indeed
other classes of binuclear metallohydrolases, MBLs
exhibit several distinctive features. The presence of
Cys, as found in the active site of B1 enzymes, is
unusual in catalytic, as opposed to structural, zincPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.centers [88], as is the absence of any metal-bridging
protein group (e.g., a carboxylate side chain), although
these are present in other members of the wider MBL
superfamily [89]. Understanding of the relationship
between the different MBL classes and the widern, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
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comparisons indicate that the subclass B3 MBLs are
most closely related to other members of the super-
family; and it has been proposed that these are
sufficiently distinct from theB1 andB2MBL subclasses
for them to be considered as a separate β-lactamase
group [90]. For many years from their identification in
1966 [91], MBLs were considered as primarily of
biochemical, rather than clinical, interest, but this
situation has changed with the realization that several
of the subclass B1 enzymes, notably NDM (NewDelhi
MBL) in Enterobacteriaceae [92] and VIM (Verona
IMipenemase) in non-fermenting organisms, particu-
larly P. aeruginosa [93], are disseminating widely on
mobile genetic elements. Indeed, the extent of NDM-1
dissemination on a variety of genetic supports has ledFig. 7. Possible mechanism of carbapenem hydrolysis b
binding displaces Zn-bridging hydroxide to a terminal position
intermediate with negative charge delocalized around the pyr
water generating (e) the Δ1 pyrroline or (f) at N4 by incoming w
product. (Note that as shown Zn-bound “apical”water is displac
to the bridging position on substrate binding.)
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asamajor contributor to carbapenem failure in resistant
Enterobacteriaceae. In contrast, subclass B2 and B3
enzymes are, with a few exceptions where association
of B3 enzymes with mobile genetic elements has been
identified [94,95], restricted to the chromosomes of
Gram-negative bacteria. The L1 enzyme of Stenotro-
phomonas maltophilia [96], a highly resistant organism
able to infect only severely compromised patients [97],
is probably the most clinically relevant of these.
The catalytic mechanism of MBLs (Fig. 7) has now
been the subject of extensive investigation, to a
great extent facilitated by the ability to substitute zinc
for more spectroscopically active metal ions such as
cobalt or cadmium, while retaining hydrolytic activity
(for review, see Ref. [98]). Against this, the diversityy binuclear class B metallo-β-lactamases. (a) Substrate
(b) enabling attack upon the scissile carbonyl. (c) Anionic
roline ring resolves either (d) by protonation at C2 by bulk
ater at the bridging position generating (g) the Δ2-pyrroline
ed by substrate; some proposals [115] show this as moving
on, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
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even the sameMBL subclass complicates the process
of identifying the most salient features of β-lactam
breakdown that might constitute a common mecha-
nism. A further issue is the long-standing debate over
the physiological importance of the binuclear center in
B1 MBLs. This arises through the differing affinities of
the Zn1 and Zn2 sites (e.g., see Refs. [99,100]) that
permit isolation of forms of the enzymes in which only
the Zn1 site is occupied [101,102], and is complicated
by the susceptibility of the Zn2-binding Cys residue to
oxidation [103–106]. The consensus view now holds
that the binuclear form of the enzyme is the most
catalytically active and predominates under physio-
logical conditions [107]. In consequence, we here
focus on mechanistic studies of the binuclear forms of
the B1 and B3 enzymes.
Mechanism of carbapenem hydrolysis by class B
β-lactamases
The studies of Waley and Benkovic provide the
foundation of much current mechanistic understanding
of MBLs. The former proposed, based on low-
temperature transient kinetic studies of Zn(II) and Co
(II)-substitutedenzymes, that reaction involvedchanges
in metal coordination during the catalytic cycle and a
branched kinetic mechanism [108,109]. The latter
conclusively supported involvement of a metal-bound
water (or hydroxide) nucleophile as opposed to
alternatives such as an anhydride mechanism [110].
Benkovic and co-workers also proposed the key
intermediate to be a ring-opened (i.e., product-like)
anionic species in which a negatively charged
nitrogen is stabilized by proximity to Zn2, which is
therefore described as a “superacid” [110,111]. This
differentiates the MBL-catalyzed reaction from pro-
posed mechanisms for other metallohydrolases (as
reviewed in, e.g., Refs. [112,113]), which emphasize
stabilization by themetal center of tetrahedral oxyanion
species formed after attack of a metal-bound water
nucleophile on the scissile bond. Although the anionic
intermediate was initially identified in hydrolysis of the
chromogenic cephalosporin nitrocefin [111], in which
formation of a conjugated system within the electron-
withdrawing dinitrostyryl C3 substituent is proposed
to help stabilize the negative charge, evidence is
accumulating for its existence in reactions with other
β-lactam classes, in particular carbapenems, where
the ability of the pyrroline ring system to tautomerize is
considered to support formation of analogous species
by enabling delocalization of the negative charge
arising from β-lactam amide cleavage [84,114]. More
recently, a combination of UV–vis [utilizing both Zn(II)
and Co(II)-substituted enzymes], NMR and X‐ray
spectroscopy, together with QM/MM and MD simula-
tions, demonstrated that MBLs of all three classes
employ a common, branched, mechanism for carba-
penem hydrolysis (Fig. 7), with bifurcation arising fromPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
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at the amide N (with proton donation from metal-
bound water at the “bridging” position) or at C2 from
bulk solvent [115]. The role of Zn1 is then primarily to
deliver the nucleophile, as evidenced by the work of
the Page group, who demonstrated that hydrolytic
activity of a series of metal-substituted MBL deriva-
tives correlates with the position of the relevant metal
ion in the activity series [83].
Accumulation of structural (crystallographic) evi-
dence in support of mechanistic proposals for MBLs
has been impededby the absenceof covalent species
along the reaction pathway and consequent difficulty
in trapping enzyme-bound states. However, several
publications [116–125] now describe structures of
enzyme-bound complexes arising from reaction of
MBLs with β-lactams in crystallo, although (in com-
mon with many other crystallographic studies of
protein:ligand complexes) the occupancy achieved
and the confidence with which the mode of ligand
binding is defined vary between them [126]. Com-
plexes of MBLs with hydrolyzed carbapenems have
now been described for the B1 enzymes NDM-1
[117,119,121] (Fig. 6a) and VIM-1 [125] (Fig. 6b), the
B2 enzyme CphA [120] and the B3 enzyme SMB-1
[122] (Fig. 6c). Importantly, the consensus from these
structures, as well as those of other complexes of
MBLs with hydrolyzed β-lactams [116–118,121,123],
supports close approach of the ring-opened nitrogen
to Zn2, consistent with the concept of the populated
anionic intermediate. However, in other aspects,
available structures of carbapenem complexes show
considerable variability. A recent study of NDM-1
[119] observed both the Δ2 and Δ1 tautomers of
enzyme-bound ring-opened imipenem and merope-
nem, consistent with the possibility of a branched
mechanism, but proposed a linear reaction pathway
whereby protonation occurs exclusively from bulk
solvent. This was evidenced by NMR experiments
which, in contrast to those in the study above, identified
only a single diastereomer of the Δ1 hydrolysis
product, and by the absence of bound water in the
Zn-bridging position, which is instead occupied by the
newly formed carboxylate at C7. By way of contrast,
carbapenem complexes of VIM-1 [125] (subclass B1)
and SMB-1 [122] (B3) exclusively show the Δ1
tautomer, but also contain a water molecule in the
bridging position interacting with the 6α-hydroxyethyl
group. Notably, these structures were obtained by
prolonged exposure to carbapenem rather than the
shorter soaks used the NDM-1 study. Taken together,
these data suggest that species formed on opening of
the β-lactam ring may feature bidentate Zn1 coordina-
tion by the product carboxylate, but that an incoming
water molecule at the bridging position may cause the
complex to reorganize, possibly involving rotation
around the carbapenem C5\C6 bond. As in other
fields, in the absence of any corroborating information
(e.g., spectroscopic information) collected in crystallo,n, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
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reaction mechanism defined using solution data
remains a challenging undertaking.
Crystallographic studies such as those above have
contributed much to our understanding of β-lactam
binding and hydrolysis by MBLs, but considerable
uncertainties remain. Most notably, structures are
lacking for any MBL-bound states in which the β-
lactam ring remains intact (i.e., Michaelis complexes)
despite efforts to trap theseusing cadmium-substituted
forms of NDM-1 [121]. Information on early stages of
the reaction is thenderived fromspectroscopic studies,
in particular the combination of rapid freeze-quenching
with electron paramagnetic resonance or X‐ray anal-
ysis of fine structure approaches. Such studies, which
haveprovided information at timepointsdown to 10ms
for carbapenem turnover by the BcII (B1) [84,115] and
L1 (B3) [127] MBLs, evidence key aspects of the
proposed mechanism for binuclear MBLs, namely,
flexible coordination of zinc ions with an increase in
coordination number on association with substrate,
and flexibility of the metal center as a whole as
evidenced by increases in the zinc– zinc separation
during the catalytic cycle. The latter point is consistent
with crystallographic data [119]. An additional consid-
eration is the existence of specific sequence/structural
requirements for turnover of carbapenems that are
more stringent than those for other substrates—a very
recent deep sequencing study of NDM-1 [128]
identified a number of positions at which mutation
affected carbapenem hydrolysis much more severely
than that of other substrates.
Computational studies of β-lactam binding and
hydrolysis by MBLs are similarly constrained by the
absence of experimental structures for the Michaelis
complex, as well as by the challenges associated
with accounting for the flexibility of coordination
geometry that is a feature of Zn(II) metalloenzyme
systems [129]. In consequence, the findings of QM/
MM studies of carbapenem hydrolysis by binuclear
MBLs vary in several aspects; notably, interactions
involving the substrate carboxylate and Zn2, which
in some cases are proposed to occur only on
formation of anionic species [130,131]; the identity
of the nucleophile, in one study [121] considered to
be bulk water rather than the bridging hydroxide; and
the protonation route(s) for N4 [131]. It is neverthe-
less encouraging that in a number of cases [131,132]
simulations both predicted free energy barriers for
carbapenem breakdown and the structures of
intermediates that closely approach those derived
from experiment.Class C β-lactamases
β-Lactamases of class C are widely distributed on
the chromosomes of many Gram-negative species.
Indeed, as the first β-lactamase to be identified, thePlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Braggint
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history of β-lactamase research. Many of the most
important opportunistic Gram-negative pathogens
carry chromosomal genes encoding class C en-
zymes, typically annotated as ampC, that under
normal conditions are not expressed. However,
derepression of these, either as a result of mutation
or through induction by specific β-lactams, can lead to
high-level expression with consequent elevation of
MICs for susceptible β-lactams [133,134]. The clinical
relevance of class C enzymes is further enhanced by
the dissemination of certain family members, such as
the CMY, FOX and DHA enzymes, on mobile genetic
elements in both Enterobacteriaceae and non-
fermenting species such as P. aeruginosa [135].
Mechanism of class C β-lactamases
In many respects, the mechanism of class C
enzymes has remained enigmatic, in large part due
to the lack of clear candidates for residues able to fulfill
the role of general base, with consequent uncertainty
surrounding both the acylation and deacylation halves
of the reaction. In the absence of the Glu166 found in
the class A active site, initial crystallographic work
[136] inspired the suggestion, based on structural
comparisons with trypsin, that Tyr150 (a residue
conserved among class C enzymes) could function
as the general base for both acylation and deacyla-
tion, but such a mechanism would require this to exist
as tyrosinate (i.e., in the deprotonated form) through-
out the reaction cycle and is not supported either by
NMR titration experiments [137] or by subsequent
high-resolution crystal structures [138] that identify
this residue as neutral (i.e., remaining protonated) at
all stages of reaction. Alternative hypotheses then
focus on the role of Lys67 from the SBL SXXK motif
and/or require involvement of bound substrate. A
further important mechanistic distinction from the
class A enzymes, identified from early crystal struc-
tures [139], is that the deacylating water molecule
approaches from the opposite face of the acylenzyme
carbonyl, that is, from the β- rather than theα direction.
While understanding of class C β-lactamase mecha-
nism remains incomplete, recent advances in this
area have exploited the several high-quality crystal
structures now available to apply increasingly sophis-
ticated computational approaches to evaluate possi-
ble mechanisms.
Computational approaches have been used to
investigate both the acylation and deacylation steps
of the class C β-lactamase reaction, although most
have focused on the latter. Several investigations
have focused on the monobactam aztreonam, for
which as a poor substrate, the crystal structure of the
wild-type acylenzyme complex is available [136]. MD
simulations of AmpC and its Michaelis complex with
aztreonam in a range of protonation states [140]
supported Lys67 as the general base for acylation. Aon, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
Fig. 8. Proposed deacylation mechanisms for class C β-lactamases. Figure shows possible schemes for hydrolysis of
generic cephalosporin acylenzyme. (a) Conjugate-base hypothesis where Lys67 deprotonates Tyr150 to activate
deacylating water molecule. (b) Substrate-activated hypothesis whereby substrate N deprotonates deacylating water.
Dashed lines denote hydrogen bonds.
14 Review: β-Lactamases and β-Lactamase InhibitorsQM/MM study of AmpC acylation by both aztreonam
and the good substrate cephalothin [141] (based on
crystal structures of the noncovalent complex
determined by the Shoichet group [142]) also
supported Lys67 acting as the general base, without
necessitating any role for substrate groups. Tyr150
was instead proposed to be involved in protonation
of the β-lactam ring N atom, acting via either a bound
water molecule or the carboxylate group of bound
substrate. This mechanism is in agreement with
experimental investigations that show Tyr150 mu-
tants to retain activity [143], as well as mechanistic
proposals based on crystal structures [142].
Proposals for the deacylation mechanism (Fig. 8)
now divide largely between those that involve the
substrate amide nitrogen (“substrate-assisted”) and
those that require coordinated proton transfers be-
tween Lys67, Tyr150 and the deacylating waterFig. 9. Class C β-lactamase active sites. (a) AmpC:imipene
attached to Ser64 (note the presence of putative deacylating w
the residues 320 and 321 in the putative C-loop associated w
dashed lines. Important residues are represented as sticks (la
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base”). The latter, first proposed on the basis of QM/
MMsimulations [144] comparing theEnterobacterP99
β-lactamase and the Streptomyces R60 DD carboxy-
peptidase (a model PBP), was apparently disfavored
by the relatively small effects upon deacylation of the
Lys67Arg mutation [145], but a more recent investiga-
tion [146] reported amore substantial loss of activity for
this mutant and concluded that the role of Lys67 was
more than simply electrostatic. A QM/MM study of
deacylation of the good substrate cephalothin [147]
identifies Lys67 as responsible for proton transfer to
Ser64 in the final stage of the reaction, with Tyr150
undergoing transient deprotonation in the acylenzyme
complex that enables its activation for deacylation.
These authors emphasize that the dynamic nature of
the acylenzyme complex, with frequent proton trans-
fers between these two residues, does not precludem complex (PDB:1LL5), imipenem acylenzyme covalently
ater adjacent to Tyr150) and (b) ADC-68 active site (note
ith carbapenem turnover). Distances (in Å) displayed as
beled), and waters are shown as spheres.
n, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
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zyme state. The alternative model for deacylation, in
which the catalytic water is deprotonated by the β-
lactam ring nitrogen, is supported by crystal structures
of acylenzyme complexes [148] and (at higher
resolution) of models of the deacylation transition
state [138], aswell as by the observation that substrate
analogues lacking an amine served as irreversible
inhibitors [149], but is disfavored by the fact that class
C β-lactamases can hydrolyze depsipeptides [150],
whichalso lack anamidenitrogen. It is entirely possible
that both mechanisms may be employed, depending
on the precise combination of enzyme and substrate
[146].
Carbapenemase activity of class C β-lactamases
Class C β-lactamases are not usually regarded as
possessing carbapenemase activity, and involvement
in carbapenem resistance is generally considered to
derive from the ability of strains that combine reduced
permeability (i.e., porin loss or mutation) with over-
expression of class C enzymes to sequester periplas-
mic carbapenems before they can reach their PBP
targets [151]. Consistent with this, affinities of class C
β-lactamases for carbapenems are generally high
[152,153], and the crystal structure of the imipenem
acylenzyme formed by E. coli AmpC (Fig. 9a [154])
reveals the carbonyl oxygen atom to be rotated
approximately 180° away from the oxyanion hole in
a binding mode reminiscent of that observed with
TEM-1 (see above). Thus, although a water molecule
is observed in the putative deacylating position and
(due in part to its approach from the β-direction) this is
not involved in interactions with the imipenem 6α-
hydroxyethyl group, the orientation of the acylenzyme
within the active site is considered unfavorable for
facile deacylation. Intriguingly, this structure (obtainedFig. 10. Active sites of class D β-lactamases and carbapene
hydrophobic bridge between Phe110 and Met221 and carboxy
(b) OXA-23:meropenem acylenzyme [PDB 4JF4; note the ca
OXA-24/40:doripenem acylenzyme [PDB 3PAE; note the
Carbapenem acylenzymes (b and c) shown as sticks covalent
lines. Note that, for consistency, residue numbering for all pan
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tion) shows imipenem bound as theΔ2 pyrroline form,
with the implication that tautomerization of the
carbapenem acylenzyme may occur slowly in class
C enzymes compared to some other β-lactamases.
Recently, however, reports haveemerged identifying
specific class C enzymes as capable of hydrolyzing
carbapenems (e.g., imipenem) in addition to extended-
spectrum cephalosporin substrates. Crystal structures
are now available for two such enzymes, the plasmid-
borne CMY-10 originally identified in Enterobacter
aerogenes [155] and the chromosomal ADC-68
enzyme from A. baumannii (Fig. 9b [156]). In both
cases, carbapenem turnover is considered to be
promoted by a 3-amino-acid deletion in the so-called
R2 loop that, by expanding the active site, may relieve
potential steric clashes with the extended C2 side
chains of many carbapenems. The presence in ADC-
68 of glycine, rather than themore bulky arginine found
in the parent ADC-1 enzyme (which doesnot hydrolyze
carbapenems), in a second, shorter loop (the C-loop)
on the opposite face of the substrate-binding cleft may
exert a similar effect [156]. As no acylenzyme structure
is yet available for a class C β-lactamase with
carbapenem-hydrolyzing activity, it remains unclear
whether and how the sequence variations described
above also promote deacylation by reorienting the
acylenzyme to facilitate attack by the deacylatingwater
molecule.Class D β-lactamases
The OXA enzymes of class D are the most diverse
and inmany respects the leastwell understoodof all the
β-lactamases. While the first enzymes identified had
activity restricted to penicillins, the OXA class now
encompasses enzymes active against cephalosporinsm acylenzymes. (a) Native OXA-23 (PDB 4KOX; note the
lated Lys82; deacylating water is shown as a red sphere).
rbapenem acylenzyme (yellow) in Δ1-pyrroline form]. (c)
carbapenem acylenzyme (cyan) in Δ2-pyrroline form].
ly attached to Ser79. Distances (in Å) displayed as dashed
els is as used by Smith et al. [185].
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to inhibitors (for reviews, seeRefs. [157,158]). Although
many members are chromosomal, dissemination of
plasmid-borne cephalosporinases in P. aeruginosa
[159], and more recently the spread of carbapenem-
hydrolyzing enzymes in A. baumannii [160] and in
Enterobacteriaceae (particularlyK. pneumoniae [161]),
has increased the clinical significance of this class. The
recent identification of OXA enzymes in a variety of
Gram-positive species [162] is further indication of the
exceptionally wide distribution and diversity of these
enzymes.
Although plasmid-borne oxacillin resistance arising
from carriage of OXA enzymes was described in the
1960s [28,163], and OXA enzymes responsible for a
range of resistance phenotypes continued to be
identified in subsequent years [157,158], it was not
until the turn of the millennium that the first OXA crystal
structures became available [164,165]. The break-
through in understanding of OXA mechanism arose
from thework ofMobashery and co-workers [166], who
identified carboxylation of the conserved active-site
lysine (the equivalent of Lys73 in class A enzymes) as
the key determinant of activity and demonstrated that
this arose from reversible reaction with atmospheric
carbon dioxide. (It was subsequently shown that
acylation of the related BlaR signal sensor responsible
for regulating expression ofS. aureusBlaZ in response
to β-lactam challenge is similarly dependent on lysine
carboxylation [167,168].) This unexpected finding (prior
to this discovery, carboxylated lysine residues were
known only as components of protein metal binding
centers) suggested carboxylated lysine as the clear
candidate for thegeneral base for both theacylationand
deacylation halves of the reaction. This conclusion is
supported by subsequent structural work (comparisons
with class A enzymes place theOXA lysine carboxylate
in a near equivalent position to that of Glu166 [169]), by
the inability of lysine mutants to support deacylation
[170], and by the results ofQM/MMsimulations ofOXA-
23 [171]. The relative hydrophobicity of the OXA active
site, which contains markedly more non-polar surface
area than the equivalent region of class A β-lactamases
[164], is then proposed to contribute to activity by
modifying the lysine pKa to favor carboxylation. It
should, however, be noted that in many [170] but not
all [166] cases, lysine mutants retain a residual (though
greatly impaired) ability to support acylation (as
evidenced by their utility in generating acylenzyme
complexes for crystallographic studies). These results
indicate that other properties of the OXA active site,
besides the presence of the carboxylated lysine, also
contribute to activation of the nucleophilic serine.
Carbapenem hydrolysis by OXA β-lactamases
Much recent effort in the field has concerned the
interactions of OXA enzymes with carbapenems,
which remains an area of active investigation. WithinPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
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enzymes are generally accepted as being able to
hydrolyze carbapenems [158], although it has been
proposed, primarily on the basis of their ability to
elevate carbapenem MICs in less permeable back-
grounds such as Acinetobacter, that all OXA enzymes
can be considered as carbapenemases [172]. Of the
five recognized groups of OXA carbapenemases, four
(OXA-23, OXA-24/40, OXA-51 and OXA-58) are
primarily associated with resistance in A. baumannii,
with the OXA-51 group comprising a range of intrinsic,
predominantly chromosomal enzymes that can confer
resistance when over-expressed as a result of, for
example, insertions in promoter sequences [173] and
the others more usually associated with plasmids
[174,175]. In contrast, enzymes of the OXA-48 group
are found onplasmids in theEnterobacteriaceae [176],
where they represent a growing challenge to clinical
microbiologists due to their increasingly common
involvement in carbapenem failure and the difficulties
associated with their detection [161,177,178].
Given the diversity within the OXA family, it is
perhaps not surprising that variability is evident in the
interactions made by carbapenems with OXA carba-
penemases. OXA-24 was the first such enzyme for
which a crystal structure became available [179]; this
revealed a closed tunnel within the active site, created
by close contacts between Tyr112 and Met223 on
opposite sides of the substrate-binding cleft, that
was proposed to orient the carbapenem for hydrolysis
via interactions with the 6α-hydroxyethyl group. The
deleterious effects of mutations at these positions
confirmed the importance of these residues to
carbapenem turnover. However, a subsequent struc-
ture of a doripenem acylenzyme complex of OXA-24
(isolated bymutation of Lys82) suggested instead that
Tyr112 and Met223 serve to constrain the orientation
of the C3 substituent of bound carbapenem, in so
doing favoring retention of the Δ2 configuration for the
pyrrolidine ring (Fig. 10c [180]). The Δ2 tautomer is
also observed in a doripenem complex of OXA-51
[181], although here the presence of Trp at position
222 (equivalent to Met223) is proposed to impair
carbapenem binding [182]. A similar so-called “hydro-
phobic bridge” between the equivalent residues
Phe110 and Met225 is also present in a structure of
OXA-58 complexed with the carbapenem analogue
6α-hydroxymethyl penicillin [183], although this is not
evident in the uncomplexed enzyme [184] and is thus
proposed to form on substrate binding. Uncomplexed
OXA-23 (Fig. 10a) also contains an equivalent
hydrophobic bridge, between Phe110 and Met 221,
but in this case, the structure of a carbapenem
complex (here obtained at low pH, rather than by
mutation of lysine) showed binding of theΔ1 tautomer
(Fig. 10b [185]). Very recently, a more comprehensive
mutational study indicated that the effects of substi-
tutions at individual bridge residues on carbapenem
turnover are substrate-dependent. Structures ofn, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
Fig. 11. Interactions of β-lactamases with β-lactamase inhibitors. (a) Vaborbactam bound to class A CTX-M-15 (PDB 4xuz).
(b) Avibactam bound to CTX-M-15 (PDB 4hbu). (c) A cyclobutanone bound to subclass B2 metallo-β-lactamase SPM-1 (PDB
5ndb). (d) A bicyclic boronate bound to subclass B1 metallo-β-lactamase VIM-2 (PDB 5fqc). Inhibitor molecules and the protein
residues they interact, with are shown as sticks. Ligand interactions are shown as colored dashes.
17Review: β-Lactamases and β-Lactamase Inhibitorsimipenem and meropenem complexes of a double
mutant lacking the hydrophobic bridge, however, both
revealed the binding of the Δ1 pyrroline, but in the R,
rather than S, form. It was concluded that in the wild-
type enzyme the bridge residues select against the
Δ1-R tautomer via steric hindrance but do not favor
the Δ2 over the Δ1-S form [186].
The multiple structural studies described above thus
indicate that, while OXA carbapenemases of Acineto-
bacter remain a heterogeneous group, the presence of
anactive-site hydrophobic bridge represents a common
structural feature that is an important contributor to
activity toward carbapenems. In contrast, OXA-48 is
only distantly related to theAcinetobacter enzymes and
instead is closer in sequence to enzymes such as the
OXA-10 group that are not usually considered as
carbapenemases. Consistent with this, the crystal
structure [187] shows that OXA-48 lacks an active-sitePlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Braggint
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.hydrophobic bridge, an observation that may also
explain the retention of activity against other substrates
(oxacillin) that are poor substrates for other OXA
carbapenemase types [188]. However, molecular
dynamics simulations of docked carbapenems support
a role for some equivalent residues (OXA-48 Thr213
and Arg214) in making interactions with the methyl
group of the carbapenem 6α-hydroxyethyl substituent.
Furthermore, exchanging the 10-residue loops con-
necting strands β5 and β6 in OXA carbapenemases
(OXA-23,OXA-24 orOXA-48) onto the backbone of the
OXA-10 enzyme (not considered a carbapenemase)
resulted in acquisition of activity against imipenem
[189]. This result suggests that, despite differences in
sequence and in the nature of their interactions with
bound carbapenem, the β5–β6 loop (that bears, e.g.,
Met221 of OXA-24) is a determinant of activity against
carbapenems across the range of OXA enzymes.on, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
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18 Review: β-Lactamases and β-Lactamase InhibitorsTaken together, these studies identify a number of
factors contributing to carbapenem hydrolysis by OXA
enzymes. First, structures of carbapenem complexes
[180,181,185] indicate that the active-site architecture,
particularly the hydrophobic bridge, imposes steric
constraints upon the orientation and preferred tauto-
meric form of the carbapenem acylenzyme. Second,
evidence both from modeled complexes [187] and
experimental structures (in particular the observation of
alternative orientations for the 6α-hydroxymethyl group
of 6α-hydroxymethyl penicillin in OXA-58 complex
structures [183]) also suggests that, as for the class A
carbapenemases (see above), specific interactions
involving the carbapenem 6α-hydroxyethyl substituent
may be important in positioning and orienting the
deacylating water molecule. Lastly, it has also been
proposed [184,185] that steric clashes with the
carbapenem 6α-hydroxyethyl group may lead to
expulsion of water from the active site on acylation by
carbapenems, requiring recruitment of a deacylating
water molecule from bulk solvent. As a result,
carbapenem turnover may also be dependent on
access of water to the active site, such that conforma-
tional changes in the acylenzymemay be necessary to
provide this [185].Recent observations [190], however,
demonstrate that OXA-48-catalyzed carbapenem
breakdown can generate lactone species (most likely
arising through intramolecular cyclisation of the acy-
lenzyme) alongside the usual hydrolysis products. This
indicates that for some (1β-methyl) substrates it is
possible to resolve the carbapenem acylenzyme
without a requirement for a deacylatingwatermolecule.β-Lactamase inhibitors
Alongside improvements to β-lactams them-
selves, combinations of susceptible β-lactams with
mechanism-based β-lactamase inhibitors represent
the major strategy for combatting β-lactamase-
mediated resistance [191]. Since the discovery and
development of clavulanic acid (Fig. 1, 7 [192]) as an
irreversible inhibitor of themost widely distributed class
A enzymes (e.g., the TEM, SHV and CTX-M classes
[193,194]), penicillin-inhibitor combinations (amoxicillin–
clavulanate, ampicillin–sulbactam, piperacillin–
tazobactam) have found wide application as treat-
ments for both community- and, particularly, healthcare-
associated infections by β-lactamase-producing
organisms [195]. However, their limited spectrum of
clinically useful activity, which is confined to a subset
of class A enzymes that, importantly, does not include
KPC [196], coupled with the emergence and dissemi-
nation of insusceptible β-lactamase types, necessi-
tates better treatment options for β-lactamase-
producing organisms. The search for more widely
effective β-lactamase inhibitors is given added impetus
by the continued weakness of the antibiotic discovery
pipeline for Gram-negative bacteria [197,198]. Fortu-Please cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
Century, Journal of Molecular Biology, https://doi.org/10.1016/j.jmb.nately, in recent years, this process has borne fruit, with
representatives of two new inhibitor classes now in the
clinic and further compounds and combinations in
development.
Space considerations, together with the availability
of several excellent recent reviews [199–202], restrict
comments on inhibitors to a relatively brief con-
sideration of some of the most important recent
advances. Chief among these is the introduction of
the diazabicyclooctanones (DBOs), of which avibac-
tam (formerly NXL-104; Fig. 1, 8) was the progenitor
and first to reach the clinic as a combination with the
oxyiminocephalosporin ceftazidime [203]. Avibactam
is a mechanism-based non-β-lactam β-lactamase
inhibitor, based around a bicyclic core structure, that
is able to acylate the active site of serine β-lactamases
in a reversible manner [204]. This contrasts with
previous (β-lactam-based) inhibitor classes, where
acylation is followed by rearrangement and fragmen-
tation events that ultimately lead to irreversible inhibi-
tion, as liberation of compound from the active site
normally leads to recyclization and regeneration of
active inhibitor. Avibactam is a potent inhibitor of β-
lactamases of classes A, including KPC enzymes, and
C, and the ceftazidimecombination is nowapproved for
conditions including complicated intra-abdominal and
urinary tract infections, and hospital-acquired and
ventilator-associated pneumonias [205]. The success
of avibactam has also stimulated development of a
number of alternative DBOs, of which the Merck
compound relebactam (Fig. 1, 9 [206]) is at the most
advanced stage of development as a combination with
imipenem. In thesecompounds, thepoints of difference
occur in theC2, C3 andC4 substituents, which in some
cases results in addition of weak antibacterial activity,
arising through PBP inhibition, to complement β-
lactamase inhibitory action [207,208,256].
The success of DBOs has driven extensive inves-
tigation of their interactions with β-lactamases of
multiple structural classes,with the result that inhibition
kinetics [207,209–212], together with a number of
crystal structures [213–217] (Fig. 11b), are now
available for interactions of avibactam in particular
with representative enzymes of classes A, C and D. A
particular focus of these efforts is the drive to
understand determinants of the fate of the acylenzyme
complex, which can resolve by recyclization [204] but
in some systems, particularly KPC, can also deacylate
to generate inactive compound [209]. Evidence from a
number of high-resolution structural studies now
indicates that the avibactam acylenzyme is able to
adopt distinct conformations, differing in the distance
between and relative orientation of the N6 and C7
atoms involved in the recyclisation reaction, and
whose relative occupancies may provide an indicator
of acylenzyme stability [218]. A further complication is
the observation of desulfation of the acylenzyme in
complexes with KPC, which may be associated with
the greater propensity for deacylation in this systemn, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
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19Review: β-Lactamases and β-Lactamase Inhibitors[204,214,219]. The extent to whichmodifications of the
DBO scaffold and/or mutation of the enzyme target
influence these processes is a matter of much current
interest. As DBOs have only recently been introduced
to the clinic, understanding of the propensity for
resistance remains limited, but variants with reduced
DBO susceptibility have been generated in the
laboratory for both the KPC [219–221] and AmpC
[222–224] enzymes, and a few reports of KPC
mutations in clinical strains unresponsive to DBO
therapy have now emerged [225–227].
Boronate-based compounds represent a second
novel scaffold for β-lactamase inhibitor development.
The propensity of boron to adopt a tetrahedral
geometry enables it to effectively mimic transient
tetrahedral species formed during hydrolytic reactions
[228], with the result that for some years boronates
have found quite extensive application both as
inhibitors and as tool compounds in studies of β-
lactamase action aimed at mimicking the tetrahedral
oxyanion transition states of either the acylation or
deacylation reactions (for selectedexamples, seeRefs.
[138,229,230]). More recently, however, development
of cyclic boronates as broad-spectrum inhibitors of
serine β-lactamases [231] has resulted in introduction
to the clinic of the combination of meropenem with the
cyclic boronate vaborbactam (Fig. 1, 10) as a treatment
for complicated urinary tract infections [232]. Vabor-
bactam potently inhibits β-lactamases of classes A
(Fig. 11a and c), but activity does not extend to OXA
enzymes or to the MBLs [233].
Inhibition of MBLs
Introduction to the clinic of DBO and vaborbactam
combinations dramatically increases treatment op-
tions for serious infections by Gram-negative bacteria.
However, neither is effective against the class B
(metallo) enzymes, and these now constitute the
major challenge for β-lactamase inhibitor develop-
ment. Indeed, despite extensive academic effort, no
MBL inhibitor is yet close to the clinic. The advent of
NDM as a highly mobile MBL in Enterobacteriaceae
has dramatically increased the clinical importance of
MBLs, with the recent observation that MBLs can
weakly degrade avibactam (and by implication other
DBOs) serving to further emphasize their growing
importance. MBL inhibitor development has largely
focused on compounds that bind and/or chelate the
zinc ions of the active site [200–202]. The natural
compound aspergillomarasmine A inhibits the MBLs
NDM-1 and VIM-2 by chelating and removing the
active site zinc ions and has been shown to be
effective against NDM-1-expressing K. pneumoniae
in mice [234]. Inhibitors that strongly bind to the
active site zinc ions include thiol-based compounds
such as the bisthiazolidines, small bicyclic com-
pounds that are effective against B1, B2 and B3
MBLs [235]. Phosphonate-containing compounds (6-Please cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Braggint
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been shown in vitro to inhibit B1 and B3 MBLs by
interacting with the di-zinc metal center, with inhibition
constants in the nanomolar range [236]. More
recently, virtual screening combined with NMR
resulted in compounds that bound in the active site
of VIM-2, but importantly did not ligand the metal ions
[237]. To date, the most promising MBL inhibitors are
the bicyclic boronates (Fig. 1, 11), compounds that
have been shown to inhibit both SBLs and MBLs
(Fig. 11d) by mimicking the tetrahedral oxyanion
formed during β-lactam hydrolysis [238]. Their activity
extends to NDM-1, and other B1 enzymes, as well as
the SBLs CTX-M-15 and OXA-48 [239]. Indeed, a
bicyclic boronate (VNRX-5133) in combination with
the fourth-generation cephalosporin cefepime is
now in phase 1 clinical trials. However, we recently
demonstrated that bicyclic boronates were ineffective
against the B3 enzyme L1 [240], indicating that
their combinations might not be effective against
S. maltophilia. Identification of compounds such as
thesewith true pan β-lactamase inhibitory activity, that
is, able to inhibit both MBLs and SBLs, remains an
ultimate goal in the field; the success of cyclic
boronates justifies further exploration of β-lactams
[241] or analogues such as cyclobutanones [242,243]
(Fig. 11c) where evidence exists that such broad-
spectrum activity is also achievable.
Encouraging results have also emerged from recent
investigations of alternative approaches to MBL
inhibition. The concept of generating covalent inhib-
itors able to attach to the highly conserved active-site
Lys224 of B1 MBLs was first explored by Kurosaki
et al. [244], who demonstrated that Lys224 reacted
with activated esters of 3-mercapto propionic acid.
More recently, the selenium compound ebselen was
shown to attach to Cys221 of NDM-1 [245]; the two
approaches have subsequently been combined to
create a dual covalent inhibitor, reacting with both
Cys221 and Lys224, active against multiple MBLs of
subclasses B1 and B2 [246]. A second rewarding
approach [247] has been to use colloidal bismuth
sulfate (identified from screens of metal compounds)
to displace Zn(II) from the NDM-1 active site,
generating an inactive Bi(III) complex. Importantly,
ebselen and colloidal bismuth sulfate are respectively
in trials or clinical use as therapies for other conditions,
constituting grounds for optimism that the process of
gaining clinical approval may be simpler than for truly
novel agents. Despite such progress, inhibition of
MBLs remains a challenging undertaking, not least
due to the requirement for selectivity over other Zn(II)
metalloenzymeswithin and beyond (e.g., angiotensin-
converting enzyme) the MBL superfamily. Achieving
potency across the range of MBL enzymes and
subclasses is also not trivial; aside from the more
obvious divergence of subclass B3 enzymes (as
evidenced by the lack of activity of bicyclic boronates
against L1) important variation also exists withinon, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
2019.04.002
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enzymes such as VIM.Concluding Remarks
Several factors have combined to transform the
β-lactamase field in recent years. The ubiquity of
ESBLs has driven use of carbapenems as empiric
therapy for Gram-negative bacteria, leading to
dissemination of carbapenemases, particularly in
Enterobacteriaceae, that challenge our ability to treat
many such infections. In addition to the ongoing
proliferation of the KPC enzymes, the association of
NDM-1 and OXA-48 with carbapenem resistance in
K. pneumoniae has provided new impetus for funda-
mental biochemical studies of β-lactamases of classes
B and D, respectively. Furthermore, the explosion in
genome sequence information has identified candidate
β-lactamases in organisms and environments not
previously considered as likely to harbour such
enzymes [248,249], as well as in organisms formerly
regarded as niche pathogens that have attracted
renewed attention as potential agents of bioterrorism
or biological warfare [102,250–252].
Fundamental biochemical questions surrounding
β-lactamase activity nevertheless remain. For en-
zymes of classes A and C, debate still surrounds the
respective acylation and deacylation mechanisms in
particular, while for the metallo-β-lactamases under-
standing of the early events in the reaction cycle
remains far from complete, in no small part due to the
absence of any covalent reaction intermediate. The
situation is slowly improving as availability of more
and better quality crystal structures and increased
access to higher-performance computing facilities,
respectively, provide more accurate models for
mechanistically important species and permit appli-
cation of high-level computational methodologies to
systems of this size and complexity and over
biologically more relevant timescales. When coupled
with technological advances in fields such as in
crystallo spectroscopy [253], neutron diffraction and
SFX, the prospects for significant advancement in
understanding of β-lactamase mechanism are good.
Against this, the extensive diversity of both enzyme
and substrate in β-lactamase:β-lactam reactions
demands caution in extrapolation of results from a
single model system to more general conclusions.
The above comments are particularly relevant when
considering carbapenem hydrolysis. While the last
decade has provided great advances in understanding
how enzymes considered as having carbapenemase
activity bind and hydrolyze these substrates, questions
remain. In particular, the relationship betweenpyrroline
tautomerization and acylenzyme hydrolysis (i.e., the
extent and basis of the stability to deacylation of theΔ1
tautomer, particularly in the OXA enzymes) is yet to be
established. While the Δ1-pyrroline is observed inPlease cite this article as: C. L. Tooke, P. Hinchliffe, E. C. Bragginto
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acylenzymes, spectroscopic studies of SHV-1 [60]
remain as the strongest direct evidence for its
increased stability to hydrolysis compared to the Δ2
acylenzyme. The basis for this slow deacylation
remains uncertain: conformational changes associated
with formation of the Δ1 species may variously
reposition the acylenzyme carbonyl outside the oxya-
nion hole (SHV-1 [59,60]), or reorient the 6α-
hydroxethyl group toenable interactions that deactivate
(e.g., with BlaC Glu166 [61]) or destabilize (e.g., with
the carboxylated lysine of OXA enzymes [254]) the
deacylatingwatermolecule. A further possibility is that
the lack of a proton at N4 of the Δ1-acylenzyme
perturbs the active-site hydrogen bonding networks
that activate the general base for deacylation [180].
Furthermore, while carbapenemases of classesAand
D may both adopt strategies to constrain the
orientation of the carbapenem 6α-hydroxyethyl
group, the implications of these for binding/activation
of the deacylating water molecule may differ in
different systems. The interactions of carbapenems
with β-lactamases of class C remain much less well
understood, and the basis for both carbapenem
inhibition of the majority of these enzymes,and
carbapenem turnover by exceptions such as CMY-
10 and ADC-68 remains unclear.
Aside from continuing investigations of underlying
biochemistry, future directions ofβ-lactamase research
will be in large part directed by the emergence and
dissemination of resistance phenotypes in the clinic.
An open question is then how the overall β-lactamase
profile of bacterial pathogenswill respond to the clinical
application of the newwaveof β-lactamase inhibitors. It
may be reasonable to predict that MBL-producing
strains may become even more prevalent, given that
these enzymes continue to avoid inhibitor combina-
tions at or near to clinic, but reports of β-lactamase
mutations resulting in insusceptibility to avibactam in
clinical isolates carryingKPC [226,255] or CTX-M [225]
enzymes, as well as in vitro generation of resistant
mutants, demonstrate the existence of multiple poten-
tial routes to failure of DBO combinations. Of course,
many precedents, including the emergence of KPC
and NDM enzymes, also exist to suggest that
previously unknownenzymeswith distinctive biochem-
ical properties may mobilize in response to usage
changes in β-lactams and inhibitor combinations.
Identifying the reasons behind the successful large-
scale dissemination of enzymes such as those above,
when others with similar biochemical properties remain
confined to occasional isolates or niche pathogens,
may help to estimate the clinical significance of
new sequences and enzymes as they continue to be
discovered. It is a certainty that the selection pressure
imposed by new β-lactams and, particularly, inhibitor
combinations will change the landscape of β-
lactamases, but much more difficult to predict the
ways in which this will occur.n, et al., β-Lactamases and β-Lactamase Inhibitors in the 21st
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21Review: β-Lactamases and β-Lactamase InhibitorsThe long history and extensive literature of β-
lactamase research might suggest a mature field
lacking in scope for discovery science. We would
instead argue that the response of the bacterial
population to the selection pressure imposed by
the continuing clinical importance of β-lactams and
of new β-lactam based therapies, the wealth of new
enzymes identified through the explosion in micro-
bial sequence information, and the application of
new technological advances, together create rich
opportunities both for fundamental biochemistry
and innovative drug discovery that are underpinned
by the pressing need to overcome antimicrobial
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